Thermo Fisher Scientific Launches PPD CorEvitas Chronic Hand Eczema Registry
New registry will generate robust real-world evidence on disease burden, treatment patterns, and long-term effectiveness of newly approved and emerging therapies.
WALTHAM, Mass., 8 June 2026 — Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the PPD™ CorEvitas™ Chronic Hand Eczema Registry, a prospective, observational cohort registry designed to generate real-world evidence on patients being treated for chronic hand eczema in routine clinical care.
The new registry, which is open to enrollment in North America, will like all CorEvitas Registries feature primary collection of proprietary, prospectively collected clinical data to support evaluation of disease history, treatment patterns, comorbidities, and the long-term effectiveness of newly approved and emerging therapies.
“Chronic hand eczema can be difficult to manage because symptoms often persist due to occupational exposures, affecting patients’ day-to-day activities, work productivity and quality of life,” said Dr. Peter Wahl, vice president and global head of scientific affairs for PPD CorEvitas Clinical Registries. “A unique feature of this registry is collection of patient-reported symptoms, treatment experience and quality of life and work productivity at 7 days and 30 days post-drug initiation, capturing the patient’s perspective on rapid response to a new treatment.”
Chronic hand eczema is a common inflammatory skin condition characterized by persistent hand dermatitis that lasts more than three months or recurs at least twice a year1. The condition is often multifactorial, involving genetic predisposition, environmental factors and triggers such as irritants and allergens1. It is also the most frequent occupational skin disease, particularly among workers exposed to “wet work,” including health care workers, food handlers and hairdressers2.
Physician-diagnosed chronic hand eczema affects 9.6% of U.S. adults3, and the condition can interfere with daily activities and have a significant negative impact on quality of life and patients’ ability to earn a living.
CorEvitas Clinical Registries are proprietary multi-drug disease registries conducting primary data collection of disease activity and treatment outcome measures to support regulatory grade evidence needs to drive regulator clinical stakeholder decision-making.
To learn more about CorEvitas Clinical Registries and this newly launched registry, request information at CHEregistry@thermofisher.com.
References
- Chronic Hand Eczema (CHE): A Narrative Review – PMC
- Chronic hand eczema – UpToDate
- Chovatiya R, Balu S, et al. Prevalence of self-reported physician diagnosis of Chronic Hand Eczema in adults: A cross-sectional study of more than 10,000 participants in the general population – Results from the CHECK study in the United States. Presented at: 2026 Winter Clinical Hawaii, January 16-21, Maui.
Key facts
| Product | PPD™ CorEvitas™ Chronic Hand Eczema Registry |
| Category | Prospective, observational cohort registry |
| Geography | North America |
| Status | Launched and open to enrollment |
| Purpose | To generate longitudinal, regulatory-grade real-world evidence on chronic hand eczema treatment in routine clinical care |
| Data collected | Selected clinician-reported outcome measures, including IGA-CHE and HECSI; patient-reported outcome measures, including HEIS, DLQI, WPAI, DermSat-7, worst skin pain and peak itch; and longitudinal data on treatment patterns, disease burden, quality of life, work productivity, and long-term effectiveness. |
| Audience | Clinicians, researchers, biopharma and biotech sponsors and stakeholders seeking real-world evidence on chronic hand eczema |
Frequently asked questions
The CorEvitas Chronic Hand Eczema Registry is a prospective, observational cohort registry designed to generate regulatory-grade real-world evidence on patients being treated for chronic hand eczema in routine clinical care.
Chronic hand eczema is a common inflammatory skin condition characterized by persistent hand dermatitis lasting more than three months or recurring at least twice a year.
The registry is designed to support clinicians, researchers, biopharma and biotech sponsors and other stakeholders seeking longitudinal evidence on chronic hand eczema treatment patterns, disease burden, and long-term effectiveness outcomes.
The registry will collect clinician- and patient-reported outcomes, treatment history, disease assessments, work productivity and quality-of-life measures and data including adverse events of special interest.
The registry addresses the need for robust real-world evidence on chronic hand eczema, including how the condition progresses, how patients are treated in routine care, and how current and emerging therapies perform over time.
Chronic hand eczema can affect daily activities, work productivity and quality of life. Longitudinal real-world data can help improve understanding of disease burden and support evidence generation for treatment decision-making and regulatory research needs.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Media contact
Mike Lawrence
Director, Communications
Email: ppdmedia@thermofisher.com